Publication & Citation Trends
Publications
0 total
Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.
Cited by 0
Semantic Scholar
763 Phase 1/2 dose escalation and dose expansion study of transCon TLR7/8 agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumor malignancies: initial results from dose escalation OA
Cited by 2
Semantic Scholar
Abstract CT252: transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors
Cited by 0
Semantic Scholar
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer OA
Cited by 33
Semantic Scholar
Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)
Cited by 0
Semantic Scholar
Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts OA
Cited by 3
Semantic Scholar
PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).
Cited by 15
Semantic Scholar
Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC)
Cited by 0
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(20)
Cancer Immunotherapy and Biomarkers
(15)
Cancer Treatment and Pharmacology
(11)
PI3K/AKT/mTOR signaling in cancer
(10)
RNA modifications and cancer
(10)
Affiliations
Roche (United States)
Carolinas Healthcare System
Memorial Sloan Kettering Cancer Center
Texas Oncology
Nektar Therapeutics (United States)